Search Results - "Banh, Lynda"

Mapping the genomic landscape of CRISPR–Cas9 cleavage by Cameron, Peter, Fuller, Chris K, Donohoue, Paul D, Jones, Brittnee N, Thompson, Matthew S, Carter, Matthew M, Gradia, Scott, Vidal, Bastien, Garner, Elizabeth, Slorach, Euan M, Lau, Elaine, Banh, Lynda M, Lied, Alexandra M, Edwards, Leslie S, Settle, Alexander H, Capurso, Daniel, Llaca, Victor, Deschamps, Stéphane, Cigan, Mark, Young, Joshua K, May, Andrew P

“…SITE-Seq probes Cas9 cleavage sites in vitro and returns a comprehensive list of off-target sites at different Cas9–sgRNA concentrations. RNA-guided…”
Get full text

Harnessing type I CRISPR–Cas systems for genome engineering in human cells by Cameron, Peter, Coons, Mary M., Klompe, Sanne E., Lied, Alexandra M., Smith, Stephen C., Vidal, Bastien, Donohoue, Paul D., Rotstein, Tomer, Kohrs, Bryan W., Nyer, David B., Kennedy, Rachel, Banh, Lynda M., Williams, Carolyn, Toh, Mckenzi S., Irby, Matthew J., Edwards, Leslie S., Lin, Chun-Han, Owen, Arthur L. G., Künne, Tim, van der Oost, John, Brouns, Stan J. J., Slorach, Euan M., Fuller, Chris K., Gradia, Scott, Kanner, Steven B., May, Andrew P., Sternberg, Samuel H.

“…Type I CRISPR–Cas systems are the most abundant adaptive immune systems in bacteria and archaea 1 , 2 . Target interference relies on a multi-subunit,…”
Get full text

Author Correction: Mapping the genomic landscape of CRISPR–Cas9 cleavage by Cameron, Peter, Fuller, Chris K., Donohoue, Paul D., Jones, Brittnee N., Thompson, Matthew S., Carter, Matthew M., Gradia, Scott, Vidal, Bastien, Garner, Elizabeth, Slorach, Euan M., Lau, Elaine, Banh, Lynda M., Lied, Alexandra M., Edwards, Leslie S., Settle, Alexander H., Capurso, Daniel, Llaca, Victor, Deschamps, Stéphane, Cigan, Mark, Young, Joshua K., May, Andrew P.

Get full text

Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells by Donohoue, Paul D., Pacesa, Martin, Lau, Elaine, Vidal, Bastien, Irby, Matthew J., Nyer, David B., Rotstein, Tomer, Banh, Lynda, Toh, Mckenzi S., Gibson, Jason, Kohrs, Bryan, Baek, Kevin, Owen, Arthur L.G., Slorach, Euan M., van Overbeek, Megan, Fuller, Christopher K., May, Andrew P., Jinek, Martin, Cameron, Peter

“…The off-target activity of the CRISPR-associated nuclease Cas9 is a potential concern for therapeutic genome editing applications. Although high-fidelity Cas9…”
Get full text

Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness by Lau, Elaine, Kwong, George, Fowler, Tristan W., Sun, Bee-Chun, Donohoue, Paul D., Davis, Ryan T., Bryan, Mara, McCawley, Shannon, Clarke, Starlynn C., Williams, Carolyn, Banh, Lynda, Irby, Matthew, Edwards, Leslie, Storlie, Meghan, Kohrs, Bryan, Lilley, Graham W.J., Smith, Stephen C., Gradia, Scott, Fuller, Chris K., Skoble, Justin, Garner, Elizabeth, van Overbeek, Megan, Kanner, Steven B.

“…Therapeutic disruption of immune checkpoints has significantly advanced the armamentarium of approaches for treating cancer. The prominent role of the…”
Get full text

CB-011, a BCMA-Specific Allogeneic CAR-T Cell Therapy, Engineered with Next-Generation CRISPR Technology to Express an HLA-E Fusion Transgene to Prevent Immune Cell-Mediated Rejection, for r/r Multiple Myeloma by Garner, Elizabeth, Degagne, Emilie, Roy, Suparna, Donohoue, Paul, Fowler, Tristan, Stanaway, Morena, Vicena, Vanina, Mutha, Devin, Schilling, Benjamin, Shaw, McKay, Bryan, Mara, Edwards, Leslie, Smith, Stephen, Kohrs, Bryan, Banh, Lynda, McSweeney, Kyle, Skoble, Justin, Kanner, Steven

Get full text

524 - CB-011, a BCMA-Specific Allogeneic CAR-T Cell Therapy, Engineered with Next-Generation CRISPR Technology to Express an HLA-E Fusion Transgene to Prevent Immune Cell-Mediated Rejection, for r/r Multiple Myeloma by Garner, Elizabeth, Degagne, Emilie, Roy, Suparna, Donohoue, Paul, Fowler, Tristan, Stanaway, Morena, Vicena, Vanina, Mutha, Devin, Schilling, Benjamin, Shaw, McKay, Bryan, Mara, Edwards, Leslie, Smith, Stephen, Kohrs, Bryan, Banh, Lynda, McSweeney, Kyle, Skoble, Justin, Kanner, Steven

Get full text

Highly Specific Cas9 and Cas12a Engineering of Human T Cells for Generation of Novel Allogeneic Cell Therapies by Donohoue, Paul, Pacesa, Martin, Lau, Elaine, Vidal, Bastien, Irby, Matthew J, Nyer, David B, Rotstein, Tomer, Loncaric, Mikey, Ciminelli, Emma, Mause, Erica Vander, Munoz, Tony, Banh, Lynda, Toh, McKenzi S, Churchward, Glen, Gonzalez, Rachel, Gibson, Jason, Kohrs, Bryan, Baek, Kevin, Owen, Arthur L.G., Slorach, Euan M, van Overbeek, Megan, May, Andrew P, Garner, Elizabeth, Jinek, Martin, Cameron, Peter

“…CRISPR-based genome editing of primary human T cells has the potential to revolutionize disease-modifying therapies. However, substantial improvements in…”
Get full text

Abstract LB009: A BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection by Garner, Elizabeth, Degagne, Emilie, Roy, Suparna, Donohoue, Paul, Fowler, Tristan, Stanaway, Morena, Vicena, Vanina, Mutha, Devin, Schilling, Benjamin, Shaw, McKay, Bryan, Mara, Edwards, Leslie, Smith, Stephen, Kohrs, Bryan, Banh, Lynda, McSweeney, Kyle, Skoble, Justin, Kanner, Steven

“…Abstract The approval and commercial launch of multiple first-generation CD19- or BCMA-directed, autologous CAR-T cell products have laid the foundation and…”
Get full text